Benjamin Levy, MD

Articles

Dr Levy on the Potential for ADCs in NSCLC

March 12th 2024

Benjamin Levy, MD, explores the potential role of antibody-drug conjugates in non–small cell lung cancer.

Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC

February 3rd 2024

Benjamin Levy, MD, discusses the mechanism of action of antibody-drug conjugates in patients with non–small cell lung cancer.

Dato-DXd for Treating Advanced NSCLC

January 26th 2024

Benjamin Levy, MD, reviews clinical data on Dato-DXd in patients with advanced NSCLC and their practical implications.

T-DXd in HER2 Mutated Advanced NSCLC

January 22nd 2024

Benjamin Levy, MD, reviews clinical data on T-DXd in HER2 mutated advanced NSCLC and their practical implications.

Molecular Testing in Advanced NSCLC

January 18th 2024

Benjamin Levy, MD, discusses the role of molecular testing in patients with advanced NSCLC.

Practice Pearls for Community Oncologists Treating Early-Stage NSCLC

August 3rd 2023

A panel of experts share unmet needs and clinical practice pearls for community oncologists regarding the treatment of patients with early-stage NSCLC.

Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab

August 3rd 2023

Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.

Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches

July 28th 2023

Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.

Consolidation Immunotherapy in Unresectable Early NSCLC: PACIFIC Study

July 20th 2023

Ben Levy, MD, reviews the 5-year update and clinical implications of the PACIFIC study which evaluated consolidation immunotherapy in unresectable early-stage NSCLC.

Treatment Strategy in Patients with Unresectable Stage I-III NSCLC

July 20th 2023

Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.

Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies

July 13th 2023

Sandip Patel, MD, and Ben Levy, MD, discuss the results and clinical implications of the IMPower-010 and KEYNOTE-091 studies of adjuvant immunotherapy in NSCLC.

Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC

July 13th 2023

A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.

Neoadjuvant Versus Perioperative Therapy in Resectable NSCLC

July 6th 2023

Expert perspectives on selecting between neoadjuvant and perioperative chemoimmunotherapy in patients with resectable early-stage NSCLC.

Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies

July 6th 2023

Sandip Patel, MD, reviews the study design, results and clinical implications of the KEYNOTE-671 and NEOTORCH studies that evaluated perioperative chemoimmunotherapy in the treatment of early-stage NSCLC.

Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study

June 29th 2023

David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC

Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

June 29th 2023

Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.

Selecting Optimal Treatment in Early-Stage NSCLC

June 23rd 2023

Ben Levy, MD offers insight into how he approaches the selection of the optimal treatment strategy in early-stage non-small cell lung cancer.

Overview of Early-Stage NSCLC and Molecular Testing

June 23rd 2023

A panel of experts who treat patients with non-small cell lung cancer provides an overview of staging, molecular testing and treatment options in stage I-IIIB non-small cell lung cancer.

The Future of Molecular Testing in NSCLC

November 9th 2022

The panel closes by highlighting unmet needs in molecular testing, and advances they are looking forward to.

Financial Considerations with Molecular Testing for Patients With NSCLC

November 9th 2022

Drs Morganstein and Ramkumar detail the financial considerations patients and physicians face during the process of molecular testing for NSCLC.